Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 8.1% | 27.9% | 30.8% | 7.9% | (10.7%) | 3.4% | 13.8% | 23.8% | 29.8% | 14.6% | 26.5% | 45.5% | 41.2% | 21.1% | 24.1% | (3.8%) | 16.7% | 12.9% | 16.6% | 18.3% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is 18.8%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for United Therapeutics Corporation have been 15.6% over the past three years, and 14.5% over the past five years.
As of today, United Therapeutics Corporation's Return on Equity (ROE) is 18.8%, which is higher than industry median of (51.8%). It indicates that United Therapeutics Corporation's Return on Equity (ROE) is Good.